{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tuberculin%2C+Purified+Protein+Derivative&page=2",
    "query": {
      "intervention": "Tuberculin, Purified Protein Derivative",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tuberculin%2C+Purified+Protein+Derivative&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tuberculin%2C+Purified+Protein+Derivative&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T13:55:15.503Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00589953",
      "title": "High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infant, Premature",
        "Erythropoietin",
        "Brain Injury",
        "Intraventricular Hemorrhage",
        "Periventricular Leukomalacia",
        "Neurodevelopmental Outcomes",
        "Randomized Clinical Trial"
      ],
      "interventions": [
        {
          "name": "Erythropoietin",
          "type": "DRUG"
        },
        {
          "name": "Saline placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atlantic Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Hours",
        "sex": "ALL",
        "summary": "Up to 24 Hours"
      },
      "enrollment_count": 22,
      "start_date": "2007-07",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2013-07-30",
      "last_synced_at": "2026-10-04T13:55:15.503Z",
      "location_count": 1,
      "location_summary": "Morristown, New Jersey",
      "locations": [
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589953"
    },
    {
      "nct_id": "NCT05807412",
      "title": "Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Rhytides"
      ],
      "interventions": [
        {
          "name": "PrabotulinumtoxinA-Xvfs",
          "type": "DRUG"
        },
        {
          "name": "OnabotulinumtoxinA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lupo Center for Aesthetic and General Dermatology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2023-05-01",
      "completion_date": "2024-02-26",
      "has_results": false,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-10-04T13:55:15.503Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05807412"
    },
    {
      "nct_id": "NCT05027958",
      "title": "Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Latent Tuberculosis Infection (LTBI)"
      ],
      "interventions": [
        {
          "name": "Tuberculin Purified Protein Derivative",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 17,
      "start_date": "2022-05-03",
      "completion_date": "2024-12-08",
      "has_results": true,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-04T13:55:15.503Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05027958"
    },
    {
      "nct_id": "NCT02332889",
      "title": "Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gliomas",
        "Medulloblastoma",
        "Neuroectodermal Tumors, Primitive"
      ],
      "interventions": [
        {
          "name": "Vaccine (autologous dendritic cells)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Decitabine and Hiltonol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 1,
      "start_date": "2015-04",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2018-05-04",
      "last_synced_at": "2026-10-04T13:55:15.503Z",
      "location_count": 3,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02332889"
    },
    {
      "nct_id": "NCT04926922",
      "title": "PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tuberculosis",
        "HIV"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 200,
      "start_date": "2021-07-27",
      "completion_date": "2026-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-04T13:55:15.503Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04926922"
    },
    {
      "nct_id": "NCT01798095",
      "title": "Equivalence Study of Specificity of PPD",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tuberculosis Infection"
      ],
      "interventions": [
        {
          "name": "Aplisol@ PPD material",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Reference Standard",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "JHP Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 152,
      "start_date": "2013-02",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-02-25",
      "last_synced_at": "2026-10-04T13:55:15.503Z",
      "location_count": 1,
      "location_summary": "Tyler, Texas",
      "locations": [
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01798095"
    },
    {
      "nct_id": "NCT00000955",
      "title": "Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Tuberculin Purified Protein Derivative",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 864,
      "start_date": null,
      "completion_date": "1992-12",
      "has_results": false,
      "last_update_posted_date": "2013-10-01",
      "last_synced_at": "2026-10-04T13:55:15.503Z",
      "location_count": 14,
      "location_summary": "New Haven, Connecticut • Wilmington, Delaware • Washington D.C., District of Columbia + 9 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000955"
    },
    {
      "nct_id": "NCT06734299",
      "title": "A Study to Evaluate Usage of Mineral Sunscreens With Differentiated Whitening Attributes in Multi-Cultural Skin Tones",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sunscreen"
      ],
      "interventions": [
        {
          "name": "Sunscreen A",
          "type": "OTHER"
        },
        {
          "name": "Sunscreen B",
          "type": "OTHER"
        },
        {
          "name": "Sunscreen C",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johnson & Johnson Consumer Inc. (J&JCI)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2024-12-06",
      "completion_date": "2025-02-14",
      "has_results": false,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-10-04T13:55:15.503Z",
      "location_count": 1,
      "location_summary": "Union, New Jersey",
      "locations": [
        {
          "city": "Union",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06734299"
    },
    {
      "nct_id": "NCT03541499",
      "title": "Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pertussis",
        "Pertussis Immunisation"
      ],
      "interventions": [
        {
          "name": "BPZE1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 50,
      "start_date": "2018-10-23",
      "completion_date": "2020-05-15",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-04T13:55:15.503Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03541499"
    },
    {
      "nct_id": "NCT01689831",
      "title": "Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tuberculosis Infection"
      ],
      "interventions": [
        {
          "name": "To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Reactivity of Aplisol compared to reference standard PPD-S2.",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "JHP Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 168,
      "start_date": "2012-05",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2012-09-21",
      "last_synced_at": "2026-10-04T13:55:15.503Z",
      "location_count": 1,
      "location_summary": "Tyler, Texas",
      "locations": [
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01689831"
    }
  ]
}